Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-08-11
1994-12-20
Schain, Howard E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514672, 514673, 514749, 514759, 514756, 514761, A61K 3125
Patent
active
053746244
ABSTRACT:
The present invention relates to fluorochemical blood substitutes used for preserving mammalian tissue having lysophosphatidyl compounds in non-toxic concentrations. More specifically, the invention relates to aqueous fluorochemical emulsions of a fluorochemical and an emulsifier useful as oxygen delivery agents and methods of preserving tissue in investigational and clinical settings, particularly those settings involving in in vivo transfusion, cardiac and other organ preservation, and in vitro organ perfusion.
REFERENCES:
patent: 4866096 (1989-09-01), Schweighardt
patent: 4895876 (1990-01-01), Schweighardt
Saunders, L., "Some Properties of Mixed Sols of Lecithin and Lysolecithin," J. Pharm. and Pharmacol., 9:834-840 (1957).
Jain, et al., "Structure of 1-Acyl Lysophosphatidylcholine and Fatty Acid Complex in Bilayers," Biochim. et Biophys. Acta, 642:203-211 (1981).
Hansrani, et al., "The Preparation and Properties of Sterile Intravenious Emulsions," J. Parenteral Science and Technology., 37:145-150 (1983).
Schmolka, I., "Theory of Emulsions," Federation Proceedings, 29:1717-1720 (1970).
Flaim, et al., "Characterization and Mechanism of Side-Effects of Imagent PB (highly concentrated fluorocarbon emulsion) in Swine," Invest. Radio., 26:S122-S128 (1991).
Man and Choy, Journal of Modular and Cellular Cardiology, 14 pp. 173-175, 1982, "Lysophosphatidyl Choline Causes Cardiac Arrythmia."
Zvezdina, et al., "Effect of Lysolecithin and Lecithin of Blood Serum on the Sensitivity of Heart to Acetylcholine," Biochem. Pharmacol. 27:2793-2801 (1978).
Jain, et al., "Association of lysophosphatidylcholine with fatty acids in aqueous phase to form bilayers," Nature 284:486-487 (1980).
Lochner, et al., "Normothermic ischaemic cardiac arrest of the isolated perfused rat heart: effects of trifluorperazine and lysolecithin on mechanical and metabolic recovery," Basic Res. Cardiol. 80:363-376 (1985).
Wenzel, D. G. and Innis, J. D., "Arrythmogenic and Antiarrythmic Effects of Lipolytic Factors on Cultured Heart Cells," Res. Comm. Chem. Pathol. Pharmacol. 41:383-396 (1983).
Imre, et al., "Membrane Stabilizing Effect of Lysolecithin in Calf Red Blood Cells," Acta Physiol. Acad. Scien. Hungar. Tomus 55:113-120 (1980).
Joist, et al., "Inhibition and Potentiation of Platelet Function by Lysolecithin," Blood 49:101-112 (1977).
Besterman, E. M. M., and Gillett, M. P. T., "Inhibition of Platelet Aggregation by Lysolecithin," Atherosclerosis 14:323-330 (1971).
Clauhan, U. P. S. and Singh, V. N., "Myocardial Phospholipid Metabolism in Alloxan Diabetic Rats," Life Sci. 22:1771-1776 (1978).
Kanaho, et al., "Mechanism of Inhibitory Effect of Some Amphiphilic Drugs on Platelet Aggregation Induced by Collagen, Thrombin, or Arachidonic Acid," Thromb. Res. 31:817-831 (1983).
Eskalinen, S. and Saukko, P., "The Hypnotic Hemolysis and the Protective Action of Lysophosphatidylcholine," Biorheol. 21:363-377 (1984).
Bergmann, et al., "Effects of amphiphiles on erythrocytes, coronary arteries, and perfused hearts," Am. J. Physiol. 240:H229-H237 (1981).
Savard, J. D., and Choy, P. C., "Phosphatidyl Choline Formation from Exogeneous Lysophosphatidylcholine in Isolated Hamster Heart," Biochim. Biophys. Acta 711:40-48 (1982).
Man, R. Y. K. and Lederman, C. L., "Effect of Reduced Calcium on Lysophosphatidylcholine-Induced Cardiac Arrythmias," Pharmacol. 31:11-16 (1985).
McGrath, et al., "Intralipid Induced Haemolysis," Brit. J. Hematol. 50:376-378 (1982).
Grimes, J. B. and Abel, R. M., "Acute Hemodynamic Effects of Intravenous Fat Emulsion in Dogs," J. Parenteral Enteral Nutr. 3:40-44 (1979).
Fisch, D. and Abel, R. M., "Hemodynamic Effects of Intravenous Fat Emulsions in Patients with Heart Disease," J. Parenteral Enteral Nutr. 5:402-405 (1981).
Burnham, et al., "Blood platelet behaviour during infusion of an intralipid-based intravenous feeding mixture," Postgrad. Med. J. 58:152-155 (1982).
Ali, et al., "The Acute Effects of Intralipid on Lung Function," J. Surg. Res. 38:599-605 (1985).
Lowe, K. C., "Artificial Blood," British Med. J. 286:1142-1143 (1983).
Lowe, et al., "Effect of a Perfluorocarbon Emulsion, Fluosol-DA, on Histamine Release from Rat Peritoneal Mast Cells in vitro," British J. Pharmacol. 82:276P (1984).
Bollands, A. D. and Lowe, K. C., "Lymphoid Tissue Responses to Perfluorocarbon Emulsion in Mice," Comp. Biochem. Physiol. 86C:431-435 (1987).
Lowe, K. C., "Perfluorocarbons as Oxygen Transport Fluids," Comp. Biochem. Physiol. 87A:825-838 (1987).
Gillett, M. P. T. and Besterman, E. M. M., "Plasma Concentrations of Lysolecithin and Other Phospholipids in the Healthy Population and in Men Suffering from Atherosclerotic Diseases," Atherosclerosis 22:111-124 (1975).
Man, R. Y. K., "Lysophosphatidylcholine-induced Arrythmias and its Accumulation in the Rat Perfused Heart," Br. J. Pharmacol. 93:412-416 (1988).
Man, R. Y. K. et al., "The Association of Lysophosphatidylcholine with Isolated Cardiac Myocytes," Lipids 25:450-454 (1990).
Sedlis, S. P., et al., "Effects of Lysophosphatidylcholine on Cultured Heart Cells: Correlation of Rate of Uptake and Extent of Accumulation with Cell Injury," J. Lab. Clin. Med. 112:745-754, (Dec. 1988).
"Lecithin," in Approved Drug Products and Legal Requirements, USPDI, 11th Ed., vol. III, (1991).
Fink, K. L. and Gross, R. W., "Modulation of canine myocardial sarcolemmal membrane fluidity by amphiphilic compounds," Circulation Research 55:585-594 (1984).
Corr, P. B. et al., "Amphipathic metabolites and membrane dysfunction in ischemic myocardium," Circulation Research, 55:135-154 (1984).
Han, X. and Gross, R. W., "Modulation of cardiac membrane fluidity by amphiphilic compounds and their role in the pathophysiology of myocardial infarction," Drug and Anesthetic Effects on Membrane Structure and Function, Aloia, Curtain and Gordon (Eds) N.Y. Wiley-Liss, at pp. 225, 243 (1991).
Jamieson and Greenwalt, Eds., Blood Substitutes and Plasma Expanders, A. R. Liss Co., pp. 1-26 (1978).
Cleman, M. et al., "Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%," Circulation, 74(3): 555-562 (1986).
"Lecithin," in USP XXII NF XVII, United States Pharmacopeial Convention, (1990).
Schain Howard E.
Touzeau P. Lynn
LandOfFree
Fluorocarbon blood substitute does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorocarbon blood substitute, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorocarbon blood substitute will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2386320